- Novo Nordisk will invest €432 million (approximately DKK 3.2 billion) to upgrade and retrofit its tabletting facility in Athlone, Ireland, to expand oral GLP-1 manufacturing capacity.
- The project will enhance supply for markets outside the US and create up to 500 construction jobs, with completion expected between late 2027 and 2028.
Novo Nordisk today announced an investment of €432 million (approximately DKK 3.2 billion) in its tabletting facility in Monksland, Athlone, Ireland. The investment is intended to provide additional manufacturing capacity for current and future GLP-1 treatments in oral form.
The project includes upgrading and retrofitting the existing facility to expand the company’s oral production capabilities. According to the company, the site will serve as a hub for supplying markets outside the United States. Construction has already begun and is expected to be completed gradually from the end of 2027 through 2028.
The facility currently employs 260 people. In addition, the expansion project, covering 45 acres (18 hectares), is expected to create up to 500 construction jobs. The company stated that the investment will strengthen supply and enhance Ireland’s role in supporting global demand for oral GLP-1 treatments.
“With the investment in the Athlone facility, Novo Nordisk is expanding its production capacities for oral products, which will strengthen our ability to meet both current and future demand, outside the US. This investment, a historic milestone for Novo Nordisk in Ireland, marks our continued commitment to Ireland and our highly skilled employees in Athlone while allowing us to make a difference for millions of people living with serious chronic diseases.”
Kasper Bødker Mejlvang, EVP CMC & Product Supply, Novo Nordisk
The company described the expansion as part of its long-term commitment to Ireland and to strengthening manufacturing capacity for oral GLP-1 therapies globally.
